Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Chlorhexidine Articles

FDA sees Sinclair's Decapinol as medical device

3 May 2004

Zila's 52% revenue increase; 54% cut in losses

24 June 2002

OraPharma's Arestin approved in USA

19 February 2001

Sumitomo to market AstraZeneca's Hibitane

24 July 2000

Oralife investors to receive C$5.4 million as firm fights to survive

15 January 1999

First Oral Periodontitis Treatment In USA

8 October 1998

Bioglan Buys Zeneca Dermatology Products

12 August 1998

Atrix Advances In Periodontal Disease

7 April 1997

ICL Postpones Perio Prods Public Offering

24 February 1997

Alpharma gets generics approval

15 January 1996

Hygenics/Clay Park agreement

26 June 1995

ISRAEL CHEMICALS UNVEILS PHARMA PLANS

28 March 1994

CHLORZOIN APPROVAL GIVES KNOWELL CAUSE TO SMILE

27 September 1993

FOREIGN INVESTMENT PROJECTS IN CHINA

16 August 1993

ICI, UPJOHN TO DROP SUMITOMO JVs

20 January 1992

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS